DNBC-FINANCIAL-GROUP
Sending money abroad has traditionally been an arduous and expensive task that frustrates users. Plus with the post-pandemic changes, people now need a faster yet cheaper contactless money transfer solution that can be done quickly on a mobile. That leads to the demand for payment apps.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220413005433/en/
But which ones are the best international payment apps ? That depends. The best payment apps are the ones that work best for your business.
DNBCnet App - Powered by the leading Digital Banking Firm DNBC
Digital banking firm DNBC was founded by Le Hung Anh in 2017, professionally known as Jimmy Lee, headquartered in Singapore.
With the mission to support enterprises as well as individuals in financial transactions over the world, DNBC has developed the DNBCnet app in order to make the banking process easier yet cheaper by adapting more innovative changes right on the app.
“DNBCnet is an all-in-one tool for any user who wants to conduct international transactions, manage and control the cash flow of their business,” said Jimmy Lee, Founder & CEO of DNBC.
DNBCnet App offers exceptional benefits
Best for corporate international money transfers
When it comes to international payments , companies just want to make quick transactions while keeping the costs as low as possible.
It can be difficult to find a provider that offers quick transfers and low fees. But if you want to keep your business straightforward, you don’t have to look very far because DNBC business accounts will fit the bill.
“If you structure payments properly, digital banking can create more predictable cash flow over the life of your business,” said CEO Jimmy Lee.
Fastest ways to send money abroad
When sending money globally, an important factor besides fees is the speed. Speedy transfer will accelerate the business, otherwise it will slow down the whole operation significantly.
With DNBCnet app , recipients will get the fund instantly if transferred in DNBC network. It only takes 1-2 business days to send to someone outside the system.
Ease of use
DNBCnet works as a mobile app, the signing up process can be done quickly with a few simple steps. It owns a seamless visual interface which allows users to handle payments in no time.
On top of that, you can keep track of your transfer and get updates along the way, so you’re always in the loop about your funds.
Utmost safety for mobile banking
Security is a must for any financial app . DNBC has raised its standard by adopting the latest technology such as two-factor authentication , data encryption for every transaction.
That will help protect account information and transactions to the fullest extent preventing any potential frauds for customers and businesses.
As a bonus perk
Besides the core function, DNBCnet also adds up a number of accompanying features to make it even more favorable. Users now can also check real-time exchange rate information, view financial statistics by charts, send mobile top up and many more.
Level up your payment practice with DNBCnet app
One of the key benefits of digital banking apps is that they allow users to manage payments anywhere and anytime. With that, business owners can focus on delivering services, not bothering with the payment process .
DNBCnet app offers exceptional convenience and transparency to its users. Via smartphones, you can find the IOS version for mobile banking on the App Store or mobile banking app for Android in the Google Store. Or simply search for DNBCnet .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005433/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom